CD274 and neoplasm: The delayed release of anti-PD-L1, hence, was able to stimulate antitumor immunity, leading to significantly delayed tumor growth (< 0.01) and improved survival (p < 0.05) compared to treatments with a single agent (gemcitabine or anti-PD-L1 hydrogels) alone.